The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin

Nicole M Gerlanc,1 Jennifer Cai,2 Joseph Tkacz,1 Susan C Bolge,2 Brenna L Brady1 1Health Analytics, LLC Columbia, MD, USA; 2Janssen Scientific Affairs, LLC Titusville, NJ, USA Objective: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used a patient survey to assess health, satisfaction, and diabetes self-management in relation to weight management.Methods: A survey including the Current Health Satisfaction Questionnaire, Diabetes Distress Scale, and Diabetes Treatment Satisfaction Questionnaire was administered using an online platform to a sample of 205 patients with T2DM prescribed canagliflozin. Patients were placed into 5 groups based on their self-reported weight change since initiation of canagliflozin: Lost >10 lbs, Lost 5–10 lbs, Lost <5 lbs, No Change, and Gained Weight. One-way ANOVAs, Kruskall–Wallis tests, and multivariable regression were used to explore differences between weight loss groups. Results: The majority of patients (66.8%) reported losing weight. Compared to other groups, patients who lost >10 lbs were more likely to be engaged in a weight loss program for at least 6 months. Patients in the Lost >10 lbs and Lost 5–10 lbs groups reported the greatest satisfaction with canagliflozin (p<0.05 for both). Multivariable analyses controlling for patient demographic and treatment characteristics revealed that losing >10 lbs was associated with reduced diabetes distress, improved A1c and blood glucose levels, and decreased perceived frequency of hyperglycemia (p<0.05).Conclusion: Increased positive patient outcomes, engagement in diabetes self-management, and medication satisfaction were observed among patients who reported weight loss. These findings suggest that a T2DM regimen that includes canagliflozin as part of a weight loss regimen can help improve patient outcomes and experiences with T2DM. Keywords: T2DM, patient outcomes, diabetes self-management, SGLT2 inhibitor, weight managemen

Aesara

Aesara is a Python library for defining, optimizing, and efficiently evaluating mathematical expressions involving multi-dimensional arrays.If you use this software, please cite it using the metadata from this file

Detection and Potential Utility of C-Reactive Protein (CRP) in Saliva of Neonates

Objective: We aimed to detect CRP in neonatal saliva and evaluate its diagnostic utility. Study Design: Salivary and serum samples (n=89) were collected from 40 neonates. Salivary CRP levels were determined using an enzyme-linked immunosorbent assay (ELISA); serum CRP was measured per hospital protocol. Correlation coefficients with 95% confidence intervals and robust linear regression measured association while receiver-operator characteristic (ROC) curves described the accuracy of salivary CRP in discriminating abnormal serum CRP thresholds of ≥ 10 mg/L and 5 mg/L. Corresponding sensitivities and specificities were calculated for these salivary cutpoints. Results: The Area Under the Curve (AUC) for salivary CRP in predicting serum CRP levels of ≥ 10 mg/L and 5mg/L were 0.81 and 0.76, respectively. The corresponding sensitivity and specificity for raw salivary CRP to discriminate a serum CRP of ≥ 5 mg/L was 0.54 and 0.95, respectively. The corresponding sensitivity and specificity for raw salivary CRP to discriminate a serum CRP of ≥ 10 mg/L was 0.64 and 0.94, respectively. A statistically significant correlation was observed between serum and salivary CRP (r = 0.62, p < 0.001). Conclusions: CRP is detectable in neonatal saliva and can predict abnormal serum CRP thresholds. Salivary CRP analysis represents a feasible screening tool for detecting abnormal serum CRP levels